Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $800.84M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
RIGL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Rigel Pharmaceuticals, Inc.NASDAQ: RIGL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $597K fell 1.2% year over year, in line with the -1.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.
Context
- Depreciation & amortization amounted to 0.8% of revenue in FY2025, down 0.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.2% toward the trailing-twelve-month pace of -1.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.42M USD
- Year-over-year change
- +8.4%
- 4-year CAGR
- +20.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.42M | +8.4% |
| FY2024 | 2024-12-31 | 2.23M | +80.0% |
| FY2023 | 2023-12-31 | 1.24M | +24.0% |
| FY2022 | 2022-12-31 | 998K | -14.1% |
| FY2021 | 2021-12-31 | 1.16M | — |
Depreciation & Amortization vs competitors
How RIGL compares with its peers on the latest reported figures
- RIGL's LTM Mar 2026 depreciation & amortization of $2.41M is the 4th largest of the 10 companies compared; the peer median is $1.18M.
- Its year-over-year change of -1.0% is the 6th highest of 9, against a peer median of +5.8%.
- Depreciation & amortization amounts to 0.8% of revenue for RIGL, versus a peer median of 9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $28.3M | -5.0% | +11.7% | 1.2% | |
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Mar 2026 | $3.38M | +84.9% | +5.3% | 9.7% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Jun 2024 | $2.04M | — | -11.5% | 31.4% | |
| LTM Mar 2026 | $1.18M | +9.0% | -11.2% | 236.0% | |
| LTM Mar 2026 | $1.17M | +120.2% | +56.5% | 222.3% | |
| LTM Mar 2026 | $997K | +3223.3% | — | 2.0% | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $314K | +2.6% | +49.5% | — | |
| Peer median (excluding RIGL) | $1.18M | +5.8% | +16.0% | 9.7% | |
Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.91M) | (58.57M) | (25.09M) | 17.49M | 367.02M |
| Depreciation & Amortization | 1.16M | 998K | 1.24M | 2.23M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (245.85M) |
| Stock-Based Compensation | 9.49M | 12.39M | 8.81M | 12.39M | 12.71M |
| Change in Working Capital | 9.72M | (29.05M) | 9.52M | 153K | (19.51M) |
| Accounts Receivables | 501K | (24.85M) | 9.77M | (11.07M) | (10.15M) |
| Inventory | (4.88M) | (2.38M) | 1.17M | 764K | (5.64M) |
| Accounts Payables | 41K | 3.79M | (366K) | (3.8M) | 3.85M |
| Other Working Capital | 14.05M | (5.61M) | (1.06M) | 14.26M | (7.58M) |
| Other Non-Cash Items | 3.43M | 481K | (213K) | (788K) | (41.13M) |
| Operating Cash Flow | 5.88M | (73.76M) | (5.74M) | 31.47M | 75.66M |
| Capital Expenditures | (627K) | (450K) | (15M) | (396K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (141.46M) | (28.89M) | (31.21M) | (35.27M) | (153.49M) |
| Sales of Investments | 62.05M | 101.23M | 41.65M | 39.7M | 61.13M |
| Other Investing Activities | 0 | 893K | 259K | 98K | 0 |
| Investing Cash Flow | (80.04M) | 72.78M | (4.3M) | 4.13M | (92.37M) |
| Debt Repayment | 0 | 19.54M | 19.95M | 0 | (7.5M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 8.1M |
| Common Stock Repurchased | 0 | 0 | 0 | (10M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 62.68M | (12.99M) | (1.58M) | (1.64M) | 0 |
| Financing Cash Flow | 62.68M | 6.55M | 18.37M | (11.64M) | 601K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.48M) | 5.57M | 8.33M | 23.96M | (16.11M) |
| Free Cash Flow | 5.25M | (74.21M) | (20.74M) | 31.08M | 75.66M |
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Intrinsic Alpha fair value
Locked
Current Price
$42.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.